Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
An insider of the issuer has filed a Form 144 notice to sell 7,315 shares of common stock through broker Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an aggregate market value of $331,390.71, while 47,374,939 shares of this class were outstanding at the time of the notice. The shares to be sold were acquired as restricted stock from the issuer on 02/22/2019 and 02/21/2020.
Over the past three months, the same seller, Jean F. Holloway, has already sold several blocks of common stock, including 10,000 shares on 11/11/2025 for gross proceeds of $461,800.00. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Artivion, Inc. executive reports charitable stock gift
An officer of Artivion, Inc., serving as VP and Chief Accounting Officer, filed a Form 4 reporting a gift of 750 shares of Artivion common stock on 12/01/2025. The transaction is coded as a gift and priced at $0, reflecting that the shares were donated rather than sold. After this transaction, the reporting person directly owns 134,630 shares of Artivion common stock. The explanation clarifies that the 750 shares were gifted to a charity.
Artivion insider James Mackin has filed a notice to sell 30,921 shares of common stock of AORT through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,430,714.67. These shares relate to an option originally granted on 03/05/2019 and acquired on 12/02/2025, with the purchase price paid in cash.
Artivion had 47,374,939 shares of common stock outstanding at the time referenced. Over the prior three months, Mackin sold 17,580 shares of common stock on 11/10/2025 for gross proceeds of $784,400.26 and 34,210 shares on 11/13/2025 for gross proceeds of $1,568,812.44. By signing the notice, he represents that he does not know of any undisclosed material adverse information about the company’s current or prospective operations.
Artivion, Inc. (AORT)11/21/2025. He exercised options to buy 20,301 shares of common stock at $18.44 per share and another 27,075 shares at $11.03 per share. On the same date, he sold blocks of 14,586 shares at a weighted average price of $44.919, 5,715 shares at $45.346, 18,705 shares at $44.91, and 8,370 shares at $45.345, with each price representing a weighted average within disclosed ranges. After these transactions, he directly owned 44,753 shares of Artivion common stock.
Artivion, Inc. (AORT) senior vice president of Clinical & MD Affairs Marshall Stanton reported insider transactions in company stock. On 11/20/2025, he sold 11,888 shares of common stock at a weighted average price of $44.14 per share, and in separate transactions sold additional shares at weighted average prices of $44.315 and $44.278 per share. The sales were reported as open-market dispositions.
On the same date, Stanton exercised stock options to buy 2,033 shares at an exercise price of $18.44 per share and 1,355 shares at an exercise price of $11.03 per share, then sold the corresponding shares. Following these transactions, he reported beneficial ownership of 44,753 shares of Artivion common stock held directly, along with vested and unexercised stock options covering 20,301 shares at $18.44 and 27,075 shares at $11.03.
A holder of AORT common stock, Marshall S. Stanton, has filed a Form 144 notice to sell 47,376 shares of common stock through Fidelity Brokerage Services on the NYSE. The issuer has 47,374,939 common shares outstanding, which shows the planned sale is small relative to the total share count.
The shares to be sold were acquired on 11/21/2025 through the exercise of two stock options originally granted on 02/23/2022 and 11/08/2022, paid for in cash. The form also reports recent sales by Stanton over the past three months, including 15,276 shares sold on 11/20/2025 for gross proceeds of $674,833.49.
Marshall S. Stanton has filed a Rule 144 notice to sell 15,276 shares of AORT common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of
The shares to be sold were recently acquired through a mix of restricted stock vesting and option exercises, including blocks of 3,917, 3,986, and 3,985 shares from restricted stock and 2,033 and 1,355 shares from options granted in
Over the past three months, Stanton has also sold 2,566 and 4,993 AORT common shares for gross proceeds of
Artivion, Inc. (AORT) director share sale disclosed
A director of Artivion, Inc. reported selling 4,200 shares of the company’s common stock on 11/18/2025 at a weighted average price of $45.098 per share, with individual sale prices ranging from $44.89 to $45.295. After this transaction, the director beneficially owns 27,189 shares directly. The price range disclosure indicates multiple trades were executed to complete the total sale.
The notice reports a planned sale of 4,200 shares of common stock of AORT by a holder under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $189,413.28 and an approximate sale date of 11/18/2025. These shares were acquired as restricted stock from the issuer on 06/06/2024, with no separate cash payment described. As context, the filing states that 47,374,939 shares of the issuer’s common stock were outstanding at the time referenced.
Artivion, Inc. (AORT) senior vice president and general counsel Jean F. Holloway reported option exercises and related stock sales in November 2025. On November 14, 2025, she exercised options to acquire 6,393 shares of common stock at $29.62 per share and sold 6,393 shares at $45.00 per share, leaving 169,801 shares owned directly, then 163,408 shares after the sale. On November 17, 2025, she exercised options for 6,394 shares at $29.62 and sold 6,394 shares at $45.17, with 169,802 shares shown after the exercise and 163,408 shares directly owned after the sale.
The derivative table shows these transactions came from stock options granted with a $29.62 exercise price and an expiration date of March 5, 2026. The filing notes that the option exercises and subsequent sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options vested in equal annual installments beginning March 5, 2020.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
